Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531, has met all trial endpoints, showing the drug ...

This would be in terms of the development of antisense oligonucleotide WVE-N531, which is being evaluated in the phase 2 FORWARD-53 study to treat patients with Duchenne Muscular Dystrophy [DMD ...

WVE-N531 showed significant improvements in functional measures and muscle health in DMD patients during the phase 2 FORWARD-53 trial. Sustained exon skipping, dystrophin restoration, and improved ...

Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular ...

The analysis was conducted after 48 weeks of treatment with 10 mg/kg WVE-N531 dosed every two weeks (Q2W). FORWARD-53 achieved all trial goals, demonstrating sustained and industry-leading exon ...

reported positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy who are amenable to exon ...

Wave Life Sciences announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy who ...

The stock rallied after the company announced positive data from the phase II FORWARD-53 study, which evaluated its pipeline candidate, WVE-N531, for treating boys with Duchenne muscular dystrophy ...

Wave Life's WVE-N531 met all Phase 2 goals, showing exon skipping, dystrophin restoration. The therapy showed a 28.6% muscle fibrosis reduction, a 50% CK decline, and decreased IL-6/MCP-1 ...

The stock rallied after the company announced positive data from the phase II FORWARD-53 study, which evaluated its pipeline candidate, WVE-N531, for treating boys with Duchenne muscular dystrophy ...